Skip to main content
Clinical Trials/CTRI/2013/02/003380
CTRI/2013/02/003380
Completed
未知

A prospective, non-interventional, cohort survey on VTE risk in patients receiving new chemotherapy for cancer - CANTARISK

Sanofi Synthelabo India Ltd0 sites4,300 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- Colorectal or Lung (SCLC or NSCLC) cancerHealth Condition 2: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Sponsor
Sanofi Synthelabo India Ltd
Enrollment
4300
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Sanofi Synthelabo India Ltd

Eligibility Criteria

Inclusion Criteria

  • Patients with:
  • colorectal or lung (SCLC or NSCLC) cancer, cytologically or histologically confirmed,
  • metastatic or locally advanced,
  • and about to start a new chemotherapy
  • Age \>\= 18 years
  • Written informed consent

Exclusion Criteria

  • Patients on:
  • Current or anticipated anticoagulant use with exception of use to maintain patency of central venous catheter only.
  • Life expectancy \< 4 months
  • Patients participating or planned to be enrolled in clinical trials with blinded study therapy

Outcomes

Primary Outcomes

Not specified

Similar Trials